Hong Kong-listed Brii Biosciences Limited executed a further on-market repurchase of 20,000 ordinary shares on 31 August 2026, paying an aggregate HK$0.02 million at prices between HK$0.905 and HK$0.91 per share. The volume-weighted average price was HK$0.9095.

Following the transaction, issued shares outstanding (excluding treasury stock) decreased to 722.03 million, representing a marginal 0.0028% contraction versus the prior balance on 25 August 2026. Treasury shares increased to 12.92 million, leaving total issued shares unchanged at 734.96 million.

The buyback forms part of the mandate approved on 16 June 2026, which authorises repurchases of up to 72.19 million shares. Cumulative repurchases under this mandate now total 200,000 shares, equivalent to 0.0277% of the share count on the mandate date.

In accordance with Hong Kong Listing Rules, Brii Biosciences is subject to a moratorium on new share issues, sales, or transfers of treasury shares until 30 September 2026.